Lpath, Inc. (NASDAQ: LPTN), the industry leader in lipidomics-based therapeutics, announced receipt of a Notice of Grant Award from the National Institutes of Health (NIH). This $145,000 Phase 1 SBIR grant will support the study of Lpath's therapeutic monoclonal antibody, Lpathomab™, in animal models of diabetic neuropathic pain and diabetic neuropathy.
Lpathomab functions like a 'molecular sponge' that binds to and neutralizes the bioactive lipid signaling molecule, lysophosphatidic acid (LPA). In this way, the LPA receptors associated with the transmission of pain through the nervous system are silenced. Lpathomab was discovered using Lpath's proprietary ImmuneY2™ drug-discovery technology.
In collaboration with researchers at the University of California, San Diego, Lpath has already generated strong, reproducible data in an accepted animal model in which significant pain relief was observed in diabetic rats after Lpathomab treatment.